TY - JOUR
T1 - Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection
AU - Mooij, Petra
AU - Mortier, Daniella
AU - Aartse, Aafke
AU - Murad, Alexandre B.
AU - Correia, Ricardo
AU - Roldão, António
AU - Alves, Paula M.
AU - Fagrouch, Zahra
AU - Eggink, Dirk
AU - Stockhofe, Norbert
AU - Engelhardt, Othmar G.
AU - Verschoor, Ernst J.
AU - van Gils, Marit J.
AU - Bogers, Willy M.
AU - Carrondo, Manuel J.T.
AU - Remarque, Edmond J.
AU - Koopman, Gerrit
N1 - Funding Information:
This work was supported by EU-funded project “EDUFLUVAC” (FP7-HEALTH-2013-INNOVATION-1, GA n. 602640), by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through several initiatives (iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), Associate Laboratory LS4FUTURE (LA/P/0087/2020), “Investigador FCT” Program (IF/01704/2014), Exploratory Research and Development Project (IF/01704/2014/CP1229/CT0001), and PhD fellowship (Ricardo Correia-SFRH/BD/134107/2017)), and by PhD fellowship (Alexandre Murad-SWE program, CAPES 2000116/2016-9) and PVE program (CAPES 407565/2013-2) and internal funding by the BPRC. Acknowledgments
Publisher Copyright:
Copyright © 2023 Mooij, Mortier, Aartse, Murad, Correia, Roldão, Alves, Fagrouch, Eggink, Stockhofe, Engelhardt, Verschoor, van Gils, Bogers, Carrondo, Remarque and Koopman.
PY - 2023
Y1 - 2023
N2 - The first exposure to influenza is presumed to shape the B-cell antibody repertoire, leading to preferential enhancement of the initially formed responses during subsequent exposure to viral variants. Here, we investigated whether this principle remains applicable when there are large genetic and antigenic differences between primary and secondary influenza virus antigens. Because humans usually have a complex history of influenza virus exposure, we conducted this investigation in influenza-naive cynomolgus macaques. Two groups of six macaques were immunized four times with influenza virus-like particles (VLPs) displaying either one (monovalent) or five (pentavalent) different hemagglutinin (HA) antigens derived from seasonal H1N1 (H1N1) strains. Four weeks after the final immunization, animals were challenged with pandemic H1N1 (H1N1pdm09). Although immunization resulted in robust virus-neutralizing responses to all VLP-based vaccine strains, there were no cross-neutralization responses to H1N1pdm09, and all animals became infected. No reductions in viral load in the nose or throat were detected in either vaccine group. After infection, strong virus-neutralizing responses to H1N1pdm09 were induced. However, there were no increases in virus-neutralizing titers against four of the five H1N1 vaccine strains; and only a mild increase was observed in virus-neutralizing titer against the influenza A/Texas/36/91 vaccine strain. After H1N1pdm09 infection, both vaccine groups showed higher virus-neutralizing titers against two H1N1 strains of intermediate antigenic distance between the H1N1 vaccine strains and H1N1pdm09, compared with the naive control group. Furthermore, both vaccine groups had higher HA-stem antibodies early after infection than the control group. In conclusion, immunization with VLPs displaying HA from antigenically distinct H1N1 variants increased the breadth of the immune response during subsequent H1N1pdm09 challenge, although this phenomenon was limited to intermediate antigenic variants.
AB - The first exposure to influenza is presumed to shape the B-cell antibody repertoire, leading to preferential enhancement of the initially formed responses during subsequent exposure to viral variants. Here, we investigated whether this principle remains applicable when there are large genetic and antigenic differences between primary and secondary influenza virus antigens. Because humans usually have a complex history of influenza virus exposure, we conducted this investigation in influenza-naive cynomolgus macaques. Two groups of six macaques were immunized four times with influenza virus-like particles (VLPs) displaying either one (monovalent) or five (pentavalent) different hemagglutinin (HA) antigens derived from seasonal H1N1 (H1N1) strains. Four weeks after the final immunization, animals were challenged with pandemic H1N1 (H1N1pdm09). Although immunization resulted in robust virus-neutralizing responses to all VLP-based vaccine strains, there were no cross-neutralization responses to H1N1pdm09, and all animals became infected. No reductions in viral load in the nose or throat were detected in either vaccine group. After infection, strong virus-neutralizing responses to H1N1pdm09 were induced. However, there were no increases in virus-neutralizing titers against four of the five H1N1 vaccine strains; and only a mild increase was observed in virus-neutralizing titer against the influenza A/Texas/36/91 vaccine strain. After H1N1pdm09 infection, both vaccine groups showed higher virus-neutralizing titers against two H1N1 strains of intermediate antigenic distance between the H1N1 vaccine strains and H1N1pdm09, compared with the naive control group. Furthermore, both vaccine groups had higher HA-stem antibodies early after infection than the control group. In conclusion, immunization with VLPs displaying HA from antigenically distinct H1N1 variants increased the breadth of the immune response during subsequent H1N1pdm09 challenge, although this phenomenon was limited to intermediate antigenic variants.
KW - antibody response
KW - back-boosting
KW - influenza
KW - non-human primates
KW - original antigenic sin
KW - primary response
UR - https://www.scopus.com/pages/publications/85170393233
U2 - 10.3389/fimmu.2023.1256094
DO - 10.3389/fimmu.2023.1256094
M3 - Article
C2 - 37691927
AN - SCOPUS:85170393233
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1256094
ER -